- Pacira’s (PCRX) post-surgery non-opioid pain medication increasingly in demand

- PCRX sees “high teens” percent sales growth for Exparel medication, new indications

- Competition heats up but PCRX has a big head start; international opportunities

The video in this report is only accessible to members

Opioid abuse in the U.S. is well recognized. According to the National Institute on Drug Abuse, in 2018 46,800 Americans died from an opioid overdose, and 1.7 million Americans suffered from substance use disorders related to prescription opioids. The Centers for Disease Control has put the "economic burden" of prescription opioid misuse at $78.5 billion a year.

Opioids are given for pain management in various settings, such as after serious surgery. Once the anesthesia wears off, the 48-72 hours afterward can be very painful. Postoperative pain management is trending away from opioids, and one healthcare company that could benefit from that is Pacira BioSciences (PCRX).  I think its shares are worth a look. Wednesday, its stock was trading around $42, up from recent coronavirus-induced low of $31 and down from a 12-month high of $50.

Approximately 30 million surgeries are done annually in the U.S., with 14 million procedures high-volume, including orthopedic, general, OB/GYN and plastic surgery. I es...

Unlock this article with a FREE 30-Day Trial!

An FSI Pro, or FSI Macro subscription is required in order to access this content.

*Free trial available only on a monthly plan

Disclosures (show)

Get invaluable analysis of the market and stocks. Cancel at any time. Start Free Trial

Articles Read 2/2

🎁 Unlock 1 extra article by joining our Community!

You’ve reached your limit of 2 free monthly articles. Please enter your email to unlock 1 more articles.

Already have an account? Sign In

Don't Miss Out
First Month Free